Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    avid100
Previous Study | Return to List | Next Study

AVID100 in Advanced Epithelial Carcinomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03094169
Recruitment Status : Recruiting
First Posted : March 29, 2017
Last Update Posted : January 23, 2019
Sponsor:
Information provided by (Responsible Party):
Formation Biologics

Brief Summary:
Approximately 90 male and female patients with documented solid tumor malignancies of epithelial origin that are locally advanced or metastatic, and either refractory to standard therapy or for whom no standard therapy is available, will be entered into this Phase 1a/2a, multicenter, open-label, dose-escalation, cohort study of AVID100. Phase 2a will include evaluation of patient with EGFR-overexpressing squamous histology non-small cell lung cancer, squamous cell carcinoma of the head and neck, and triple negative breast cancer

Condition or disease Intervention/treatment Phase
Solid Tumor, Adult Triple Negative Breast Cancer Head and Neck Squamous Cell Carcinoma Non Small Cell Lung Cancer Drug: AVID100 IV Phase 1 Phase 2

Detailed Description:

On Day 1 of study, patients will receive study drug administered by 2-hour IV infusion in a fixed 100 mL volume. AVID100 will be administered once every 3 weeks (Q3W) with administration on Day 1 of the first week, followed by a 3-week recovery period. In Phase 2a AVID100 will be administered at a dose of 220 mg/m2.

Evidence of progressive disease at any point in the study will necessitate withdrawal of the patient from further participation so that alternative management of their malignancy may be considered. All patients will be followed to further evaluate safety as well as evidence of the anti-tumor effects of AVID100 in these selected patient populations. If anti-tumor activity is observed additional patients may be added to the planned Phase 2a patient populations to further characterize these effects.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Uncontrolled, open label, non-randomized, Enrollment in the order of confirmation of eligibility, Escalating doses of study drug in sequential patient cohorts (Phase 1a). Uncontrolled, open label, non-randomised. Enrollment into three individual Phase 2a study cohorts
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1a/2a Dose Escalation Trial to Determine Safety, Tolerance, MTD, and Preliminary Antineoplastic Activity of AVID100, in Patients With Advanced or Metastatic Solid Tumors of Epithelial Origin
Actual Study Start Date : February 1, 2017
Estimated Primary Completion Date : September 1, 2019
Estimated Study Completion Date : June 1, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Dose escalation
Minimum of 1 to 3 patients per dose cohort; approximately 4 dose cohorts to be evaluated to establish the Maximum tolerated dose.
Drug: AVID100 IV
AVID100 is administered once every 3 weeks

Experimental: Phase 2a Triple Negative Breast Cancer
Addition of up to 15 patients in each of 2 subpopulations of patients with triple negative breast cancer (30 total). One group of 15 patients will have 3+ EGFR over-expression. The second group will have 2+ EGFR over-expression.
Drug: AVID100 IV
AVID100 is administered once every 3 weeks

Experimental: Phase 2a Head and Neck Carcinoma
Addition of 15 patients with squamous head and neck carcinoma. Patients will have 3+ EGFR over-expression.
Drug: AVID100 IV
AVID100 is administered once every 3 weeks

Experimental: Phase 2a Non-Small Cell Lung Carcinoma
Addition of 15 patients with squamous histology non-small cell lung carcinoma. Patients will have 3+ EGFR over-expression
Drug: AVID100 IV
AVID100 is administered once every 3 weeks




Primary Outcome Measures :
  1. Phase 1a: Determine safety and tolerability of AVID100 [ Time Frame: 6 months ]
    Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment

  2. Phase 2a: Evaluation of the preliminary antineoplastic effects of AVID100 [ Time Frame: 12 months ]
    Number of participants with objective response or stable disease


Secondary Outcome Measures :
  1. PK Profile of Total Antibody [ Time Frame: 9 months ]
    Characterization of the pharmacokinetic profile of total antibody



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria (Phase 1):

  1. Patients with a documented (histologically- or cytologically-proven) solid tumor epithelial carcinoma that is locally advanced or metastatic
  2. Patients with a malignancy that is either refractory to standard therapy, or for which no standard therapy is available
  3. Patients with a malignancy that is currently not amenable to surgical intervention due to either medical contraindications or non-resectability of the tumor
  4. Phase 1a Dose-Escalation Cohorts: Patients with measurable or non-measurable disease according to RECIST, v1.1 criteria. To include patients reasonably likely to express EGFR.

Inclusion Criteria (Phase 2a)

  1. Patients with measurable disease according to RECIST, v1.1 criteria.
  2. Patients with triple negative breast cancer who are either EGFR 2+ or EGFR 3+ by validated IHC assay.
  3. Patients with squamous non-small cell lung cancer who are EGFR 3+ by validated IHC assay.
  4. Patients with squamous cell carcinoma of the head and neck who are EGFR 3+ by validated IHC assay.
  5. Patients whose malignancy is either refractory to standard therapy, or for which no standard therapy is available
  6. Patients whose malignancy is currently not amenable to surgical intervention due to either medical contraindications or non-resectability of the tumor

Patients to be Excluded (patients must not meet any of the following criteria Phase 1 only)

  1. Women who are pregnant or lactating. Women of child-bearing potential (WOCBP) and fertile men with WOCBP partner(s), not using and not willing to use a medically effective method of contraception.
  2. Patients with known central nervous system (CNS) or leptomeningeal metastases, or spinal cord compression not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required
  3. Patients with a malignancy other than that of epithelial origin
  4. Patients with hematologic abnormalities at baseline
  5. Patients with a significant cardiovascular disease or condition
  6. Patients with a significant ocular disease or condition
  7. Patients with a significant pulmonary disease or condition
  8. History of pneumonia within 6 months prior to the first study drug administration
  9. Patients with significant gastrointestinal (GI) abnormalities
  10. Patients with non-healing wounds on any part of the body

Patients to be Excluded (patients must not meet any of the following criteria Phase 2a only)

  1. Women who are pregnant or lactating. Women of child-bearing potential (WOCBP) and fertile men with WOCBP partner(s), not using and not willing to use a medically effective method of contraception.
  2. Patients with known central nervous system (CNS) or leptomeningeal metastases, or spinal cord compression not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required
  3. Patients with a malignancy other than EGFR-overexpressing triple negative breast cancer, squamous histology non-small cell lung cancer, or squamous cell carcinoma of the head and neck.
  4. Patients with hematologic abnormalities at baseline
  5. Patients with a significant cardiovascular disease or condition
  6. Patients with a significant ocular disease or condition
  7. Patients with a significant pulmonary disease or condition
  8. History of pneumonia within 6 months prior to the first study drug administration
  9. Patients with significant gastrointestinal (GI) abnormalities
  10. Patients with non-healing wounds on any part of the body
  11. Patients without measurable disease according to RECIST v1.1
  12. Patients with an active second malignancy within the last 2 years prior to entry

Drugs and Other Treatments to be Excluded

  1. Any antineoplastic agent for the primary malignancy (standard or investigational), without delayed toxicity, within 4 weeks, 5 plasma half-lives, or twice the duration of the biological effect, whichever is shortest, prior to first study drug administration and during study with the exception of: Nitrosoureas and nitrogen mustard within 6 weeks prior to first study drug administration and during study
  2. Any other investigational treatments during study. This includes participation in any medical device or other therapeutic intervention clinical trials.
  3. Radiotherapy for target lesions within 4 weeks prior to first study drug administration and during study
  4. Herbal preparations or related over-the-counter (OTC) preparations/supplements containing herbal ingredients aimed at treating the underlying malignancy within 2 weeks prior to first study drug administration and during study
  5. Strong inhibitors and/or inducers of cytochrome P450 (CYP) isoenzyme 3A4 within 2 weeks prior to first study drug administration and during study
  6. Immunosuppressive or systemic hormonal therapy within 2 weeks prior to first study drug administration and during study.
  7. Prophylactic use of hematopoietic growth factors within 1 week prior to first study drug administration and during Cycle 1 of study; thereafter prophylactic use of growth factors is allowed as clinically indicated

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03094169


Contacts
Layout table for location contacts
Contact: Sandra Sinclair, MHA/ED, RN 832-622-1699 sandra@forbius.com

Locations
Layout table for location information
United States, Michigan
START Midwest Recruiting
Grand Rapids, Michigan, United States, 49503
Contact: Yvette C Cole, RN    616-954-5554    yvette.cole@startmidwest.com   
Principal Investigator: Nehal Lakhani, MD         
United States, New York
The Tisch Cancer Institute-Mt. Sinai Recruiting
New York, New York, United States, 10029
Contact: Monica Toscano       monica.toscano@mssm.edu   
Principal Investigator: Marshall Posner, MD         
United States, Texas
Texas Oncology Midtown Recruiting
Austin, Texas, United States, 78705
Contact: Gregory Belz    512-424-4142    gregory.belz@usoncology.com   
Principal Investigator: Jason Melear, MD         
Texas Oncology-Baylor -Charles A. Sammons Cancer Center Recruiting
Dallas, Texas, United States, 75246
Contact: Teinetta Wells    214-370-1000      
Principal Investigator: Joyce OShaughnessy, MD         
University of Texas Southwestern Medical Center Recruiting
Dallas, Texas, United States, 75390
Contact: Tammy Lightfoot    214-648-8217    tammy.lightfoot@utsw.edu   
Principal Investigator: Saad Khan, MD         
Sponsors and Collaborators
Formation Biologics
Investigators
Layout table for investigator information
Principal Investigator: Nehal Lakhani, MD START Midwest

Layout table for additonal information
Responsible Party: Formation Biologics
ClinicalTrials.gov Identifier: NCT03094169     History of Changes
Other Study ID Numbers: AVID100-01
First Posted: March 29, 2017    Key Record Dates
Last Update Posted: January 23, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma
Carcinoma, Non-Small-Cell Lung
Carcinoma, Squamous Cell
Triple Negative Breast Neoplasms
Squamous Cell Carcinoma of Head and Neck
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Carcinoma, Bronchogenic
Bronchial Neoplasms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Neoplasms, Squamous Cell
Breast Neoplasms
Breast Diseases
Skin Diseases
Head and Neck Neoplasms